{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:30:00Z","timestamp":1790706600895,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\u03949-Tetrahydrocannabivarin (THCV) is a cannabis-derived compound with unique properties that set it apart from the more common cannabinoids, such as \u03949-tetrahydrocannabinol (THC). The main advantage of THCV over THC is the lack of psychoactive effects. In rodent studies, THCV decreases appetite, increases satiety, and up-regulates energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients. The distinctions between THCV and THC in terms of glycemic control, glucose metabolism, and energy regulation have been demonstrated in previous studies. Also, the effect of THCV on dyslipidemia and glycemic control in type 2 diabetics showed reduced fasting plasma glucose concentration when compared to a placebo group. In contrast, THC is indicated in individuals with cachexia. However, the uniquely diverse properties of THCV provide neuroprotection, appetite suppression, glycemic control, and reduced side effects, etc.; therefore, making it a potential priority candidate for the development of clinically useful therapies in the future. Hopefully, THCV could provide an optional platform for the treatment of life-threatening diseases.<\/jats:p>","DOI":"10.1186\/s42238-020-0016-7","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T17:03:05Z","timestamp":1580490185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["\u03949-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes"],"prefix":"10.1186","volume":"2","author":[{"given":"Amos","family":"Abioye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladapo","family":"Ayodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Marinkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risha","family":"Patidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeola","family":"Akinwekomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6265-665X","authenticated-orcid":false,"given":"Adekunle","family":"Sanyaolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1074\/jbc.M111.296020","volume":"287","author":"S Anavi-Goffer","year":"2012","unstructured":"Anavi-Goffer S, Baillie G, Irving AJ, et al. Modulation of L-\u03b1-lysophosphatidylinositol \/ GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem. 2012;287:91\u2013104.","journal-title":"J Biol Chem"},{"issue":"2","key":"16_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195\u2013209.","journal-title":"Pharmacotherapy."},{"issue":"3","key":"16_CR3","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180.","journal-title":"P T"},{"issue":"5","key":"16_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.bjp.0707481","volume":"152","author":"AJ Brown","year":"2007","unstructured":"Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007;152(5):567\u201375.","journal-title":"Br J Pharmacol"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2165\/11588510-000000000-00000","volume":"34","author":"Y Buggy","year":"2011","unstructured":"Buggy Y, Cornelius V, Wilton L, Shakir SA. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf. 2011;34:501\u20139.","journal-title":"Drug Saf"},{"issue":"4","key":"16_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","volume":"12","author":"B Chakrabarti","year":"2015","unstructured":"Chakrabarti B, Persico A, Battista N, Maccarrone M. Endocannabinoid signaling in autism. Neurotherapeutics. 2015;12(4):837\u201347.","journal-title":"Neurotherapeutics."},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","volume":"36","author":"FD Christopoulou","year":"2011","unstructured":"Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther. 2011;36:10\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"16_CR8","doi-asserted-by":"publisher","first-page":"e0144270","DOI":"10.1371\/journal.pone.0144270","volume":"10","author":"NL Cluny","year":"2015","unstructured":"Cluny NL, Keenan CM, Reimer RA, Le Foll B, Sharkey KA. Prevention of diet - induced obesity effects on body weight and gut microbiota in mice treated chronically with \u03949-tetrahydrocannabinol. PLoS One. 2015;10(12):e0144270.","journal-title":"PLoS One"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS, Allar\u00e0 M, Bisogno T, Petrosino S, et al. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163:1479\u201394.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"16_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0269881115615104","volume":"30","author":"A Englund","year":"2015","unstructured":"Englund A, Atakan Z, Kralj A, Tunstall N, Murray R, Morrison P. The effect of five-day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol. 2015;30(2):140\u201351. https:\/\/doi.org\/10.1177\/0269881115615104.","journal-title":"J Psychopharmacol"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/228134a0","volume":"228","author":"EW Gill","year":"1970","unstructured":"Gill EW, Paton WDM, Pertwee RG. Preliminary experiments on the chemistry and pharmacology of cannabis. Nature. 1970;228:134\u20136.","journal-title":"Nature."},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1874205X01206010018","volume":"6","author":"I Grant","year":"2012","unstructured":"Grant I, Atkinson JH, Gouaux B, Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol J. 2012;6:18\u201325.","journal-title":"Open Neurol J"},{"issue":"24","key":"16_CR13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1001\/jama.2015.6199","volume":"313","author":"KP Hill","year":"2015","unstructured":"Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474\u201383.","journal-title":"JAMA"},{"issue":"10","key":"16_CR14","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/dc16-0650","volume":"39","author":"KA Jadoon","year":"2016","unstructured":"Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O\u2019Sullivan SE, Tan GD. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777\u201386.","journal-title":"Diabetes Care"},{"issue":"1","key":"16_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1017\/S0954422414000080","volume":"27","author":"G Jager","year":"2014","unstructured":"Jager G, Witkamp RF. The endocannabinoid system and appetite: relevance for food reward. Nutr Res Rev. 2014;27(1):172\u201385.","journal-title":"Nutr Res Rev"},{"issue":"4","key":"16_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.physbeh.2005.08.033","volume":"86","author":"M Jarrett","year":"2005","unstructured":"Jarrett M, Limebeer C, Parker L. Effect of \u03949-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiol Behav. 2005;86(4):475\u20139. https:\/\/doi.org\/10.1016\/j.physbeh.2005.08.033.","journal-title":"Physiol Behav"},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","volume":"205","author":"B Le Foll","year":"2009","unstructured":"Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid - oriented clinical research after CB1 antagonists. Psychopharmacology (Berl). 2009;205:171\u20134.","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"16_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and \u0394(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737\u201353.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"16_CR19","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.2337\/dc12-2303","volume":"36","author":"R Muniyappa","year":"2013","unstructured":"Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Walter M, Courville A, Hall G, Chen KY, Volkow ND, Kunos G. Metabolic effects of chronic cannabis smoking. Diabetes Care. 2013;36(8):2415\u201322.","journal-title":"Diabetes Care"},{"issue":"2","key":"16_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199\u2013215.","journal-title":"Br J Pharmacol"},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.bjp.0707124","volume":"150","author":"RG Pertwee","year":"2007","unstructured":"Pertwee RG, Thomas A, Stevenson LA, et al. The psychoactive plant cannabinoid, Delta 9-tetrahydrocannabinol, is antagonized by Delta 8- and Delta 9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol. 2007;150:586\u201394.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"16_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/sj.ijo.0802583","volume":"28","author":"C Ravinet-Trillou","year":"2004","unstructured":"Ravinet-Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28(4):640\u20138.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"16_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","volume":"156","author":"G Riedel","year":"2009","unstructured":"Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol. 2009;156:1154\u201366.","journal-title":"Br J Pharmacol"},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/bjp.2008.130","volume":"154","author":"M Solinas","year":"2008","unstructured":"Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol. 2008;154:369\u201383. https:\/\/doi.org\/10.1038\/bjp.2008.130.","journal-title":"Br J Pharmacol"},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.bjp.0706414","volume":"146","author":"A Thomas","year":"2005","unstructured":"Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG. Evidence that the plant cannabinoid D9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol. 2005;146:917\u201326.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"16_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu094","volume":"18","author":"L Tudge","year":"2015","unstructured":"Tudge L, Williams C, Cowen PJ, McCabe C. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol. 2015;18(6):1\u20139.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"16_CR27","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1038\/nutd.2013.9","volume":"3","author":"ET Wargent","year":"2013","unstructured":"Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG, Guy GW, Duncan M, Di Marzo V, Cawthorne MA. The cannabinoid D(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes. 2013;3(5):e68.","journal-title":"Nutr Diabetes"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-020-0016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42238-020-0016-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-020-0016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:32:57Z","timestamp":1611966777000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-020-0016-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1186\/s42238-020-0016-7","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}